|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
1-[(2S)-2-(dimethylamino)-3-(4-hydroxyphenyl)propyl]-3-[(2S)-1-(thiophen-3-yl)propan-2-yl]urea |
Synonyms ![]() |
(S,S)-1-[2-(dimethylamino)-3-(4-hydroxyphenyl)propyl]-3-(1-thiophen-3-ylpropan-2-yl)urea | (S,S)-21 [PMID: 27533032] |
Comments |
PZM21 is a potent, selective μ opioid receptor agonist with bias towards G-protein (Gi) activation over β-arrestin 2 recruitment [1]. This provides a compound with reduced propensity to produce common opioid side effects whilst retaining analgesic activity. PZM21 is being used experimentally for its analgesic activity. This compound is not in PubChem and its SMILES string does not retrieve any patent documents from SureChembl (late August 2016). Compare this with oliceridine, a chemically unrelated μ opioid receptor G-protein biased agonist. |
Database Links ![]() |
|
GtoPdb PubChem SID | 318164805 |
PubChem CID | 121596705 |
Search Google for chemical match using the InChIKey | MEDBIJOVZJEMBI-YOEHRIQHSA-N |
Search Google for chemicals with the same backbone | MEDBIJOVZJEMBI |
Search UniChem for chemical match using the InChIKey | MEDBIJOVZJEMBI-YOEHRIQHSA-N |
Search UniChem for chemicals with the same backbone | MEDBIJOVZJEMBI |
Wikipedia | PZM21 |